Terminated PHASE2 INTERVENTIONAL 2-arm NCT00628264

Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

Sponsor: Action Pharma A/S

Conditions Cardiac Surgery Coronary Artery Bypass Grafting Kidney Injury Valve Surgery

Updated 6 times since 2017 Last updated: May 29, 2009 Started: Mar 31, 2008 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated due to a considerably lower recruitment rate than anticipated

Other Cardiac Surgery trials with similar outcome

Browse all Cardiac Surgery trials

A PHASE2 clinical study on Cardiac Surgery and Coronary Artery Bypass Grafting, this trial is terminated or withdrawn. The trial is conducted by Action Pharma A/S and has accumulated 6 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Action Pharma A/S

Data source: Action Pharma A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gainesville, United States